AptaBio Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	3,698	3,361	323.87	48.35
Other Revenue	-0	-	-	-
Revenue	3,698	3,361	323.87	48.35
Revenue Growth (YoY)	10.03%	937.76%	569.80%	-
Cost of Revenue	2,409	3,087	262.8	11.15
Gross Profit	1,289	273.69	61.06	37.21
Selling, General & Admin	5,569	3,893	3,385	2,788
Research & Development	10,501	14,591	12,380	6,197
Amortization of Goodwill & Intangibles	11.79	21.73	23.34	14.53
Other Operating Expenses	199.64	113.05	130.03	74.48
Operating Expenses	16,825	20,989	16,965	9,544
Operating Income	-15,536	-20,715	-16,904	-9,507
Interest Expense	-2,118	-3,401	-1,183	-4.49
Interest & Investment Income	1,265	2,296	1,984	1,572
Earnings From Equity Investments	-2,653	-625.93	-4.19	-
Currency Exchange Gain (Loss)	40.15	-252.8	-29.52	-14.43
Other Non Operating Income (Expenses)	3,812	-4,651	1,688	42.49
EBT Excluding Unusual Items	-15,190	-27,350	-14,448	-7,911
Impairment of Goodwill	-475.11	-	-	-
Gain (Loss) on Sale of Investments	324.71	-452.59	-244.29	-2,654
Pretax Income	-15,340	-27,803	-14,692	-10,565
Income Tax Expense	1,006	1,575	-2,630	-
Net Income	-16,346	-29,378	-12,062	-10,565
Preferred Dividends & Other Adjustments	-	-	-195.14	-
Net Income to Common	-16,346	-29,378	-11,866	-10,565
Shares Outstanding (Basic)	27	24	22	22
Shares Outstanding (Diluted)	27	24	22	22
Shares Change (YoY)	14.40%	5.57%	0.05%	-
EPS (Basic)	-607.00	-1248.00	-532.16	-474.00
EPS (Diluted)	-607.00	-1248.00	-532.16	-474.00
Free Cash Flow	-15,335	-12,400	-15,440	-7,874
Free Cash Flow Per Share	-569.45	-526.76	-692.42	-353.27
Gross Margin	34.84%	8.14%	18.86%	76.95%
Operating Margin	-420.14%	-616.35%	-5219.25%	-19661.23%
Profit Margin	-442.04%	-874.09%	-3663.98%	-21849.26%
Free Cash Flow Margin	-414.69%	-368.94%	-4767.39%	-16284.04%
EBITDA	-15,056	-20,184	-16,364	-9,022
D&A For EBITDA	480.81	531.35	539.11	484.62
EBIT	-15,536	-20,715	-16,904	-9,507
Advertising Expenses	647.07	9	3	7.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.